201-306--which takes us up to one year ago:
See the Lehmann report. The analyst expects a succession
of positives, starting within a short time-span.
Continued insider buying -
The timing of Ariad's recent price swoon seems
particularly interesting since Gilman et al. (i.e. Ariad)
have published 2 papers in the last 3 months:
Maybe, after start of the Rapamycin PI phase, market will
start thinking about what they have accomplished.
Management seems good in ARIA but the pay off is 3yrs.+ away
and the market is looking for earnings in these uncertain times.
In the last, January 26 1997, issue of Forbes...
Ariad and the Hoechst-Ariad Genomics Center are mentioned
in this article.
Looks like $4 will buy you $1/share/year of ARIAD's R&D spending,
Lehman's Price Target $ 11
I also agree with you that it will be a while before they will be
able to collect on this technology.
After reading the 10q it looks like the company is assured of
survival til 2002. Will it have products to market by then?
ARIAD's GENE expression technolgy featured at the
American Society Of Gene Therapy Meeting
There was an apparent downgrade of ARIA from strong buy to hold.
Before the 25th Ariad had all strong buys, while now there remains
two strong buys and one hold.
and this one is from me...notice--unsuspecting, he goes up to
the watering hole for another drink
I guess I am going to have to break my rule of selling at a loss
of 20%, cause I'm there now, maybe twice that for biotech stocks,
ah the slippery slope, time to get some more? Something fishy
going on? --Mike
|
